Sean Bohen, Olema Oncology CEO
Olema Oncology makes case for its oral SERD with fresh data cut from early breast cancer trial
Olema Oncology unveiled new data from a Phase 1b/2 breast cancer trial on Tuesday, as it strives to catch up with other companies with oral …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
